Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nan Ning, China Clinical Trials

A listing of Nan Ning, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

his study adopts a multicenter, randomized, double-blind, low-medium-high dose group and placebo parallel controlled clinical study design. After screening, patients with active ulcerative colitis who meet the inclusion criteria and do not meet the exclusion criteria will be randomized by 1:1:1:1 to Hemay007 400 mg BID group, 800 mg QD …

Phase

0.0 miles

Learn More »

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.

Phase

0.0 miles

Learn More »

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

This is a multicenter, randomized, openlabel, parallel, phase III study. This study is consisting of a Screening/Washout period (14 days) and a Treatment/Observation period (12 weeks). The subjects with regular hemodialysis should stop using the phosphorus binder before the Washout period. During the Treatment period, the subjects will be randomly …

Phase

0.0 miles

Learn More »

TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

Because LGLL has continuously activated cytotoxic T lymphocytes, immunosuppressive therapy is the standard first-line therapy for T-LGLL and CLPD-NK. Previous studies showed that the overall response rate (ORR) of first-line oral immunosuppressants ranged from 21% to 85% (median: 50%). Both methotrexate and cyclosporine A are LGLL first-line treatment options, but …

Phase

2.48 miles

Learn More »

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

Phase

8.73 miles

Learn More »